Market Research Logo

Europe Ophthalmic Drugs Market Forecast 2019-2027

Europe Ophthalmic Drugs Market Forecast 2019-2027

KEY FINDINGS

Europe ophthalmic drugs & devices market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 growing at a CAGR of 4.63% during the forecast period of 2019-2027. The ophthalmic drugs and devices market is driven by an increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.

MARKET INSIGHTS

Better regulatory policies have led to the increased trust in the drugs market which is the key factor driving the growth in the Europe market. Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.

COMPETITIVE INSIGHTS

Global ophthalmic drugs market has a large number of market players but the market is dominated by companies like Sun Pharmaceuticals Industries, Ltd., Apollo Endosurgery, Allergan Inc., Merck & Co., Roche Holding AG, Valeant, Regeneron, Eyegate Pharmaceuticals, Pfizer Inc., GlaxoSmithKline, Cipla Pharmaceuticals, Senju Pharmaceutical Co., Ltd., Novartis AG, Abbott Laboratories, Bayer, and Johnson and Johnson.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Retinal Disorders Are The Highest Revenue Generating Indication
3.2.2. Prescription Drugs Are The Fastest Growing Ophthalmic Drugs Type
3.2.3. Hospital Pharmacies Are The Majorly Used Distribution Channel
3.2.4. Liquid Ophthalmic Drugs Forms Are The Widely Used Dosage Form
3.2.5. Anti-allergy Therapeutic Class Is Anticipated To Grow At A Significant Rate During The Forecast Period
3.2.6. Small Molecule Technology Is Used For The Treatment Of Eye Diseases
4. Market Determinants
4.1. Market Definition And Scope
4.2. Market Drivers
4.2.1. Increasing Geriatric Population
4.2.2. Technological Advancement
4.2.3. Rising Prevalence Of Eye Disorders
4.2.4. Increased Healthcare Expenditure
4.3. Market Restraints
4.3.1. Renowned Drugs Going Off-patent
4.3.2. Delay In Drug Approvals
4.4. Market Opportunities
4.4.1. Increase In Disorder Symptom And Improved Diagnosis Leading To Higher Treatment Rates
4.4.2. Growing Opportunities In Developing Economies
4.5. Market Challenges
4.5.1. Side Effects Related To The Ophthalmic Drugs
5. Market By Indication
5.1. Dry Eye
5.2. Glaucoma
5.3. Infection/Inflammation/Allergy
5.4. Retinal Disorders
5.4.1. Wet Age-related Macular Degeneration
5.4.2. Dry Age-related Macular Degeneration
5.4.3. Diabetic Retinopathy
5.4.4. Other Retinal Disorders
5.5. Other Indication
6. Market By Type
6.1. Prescription Drugs
6.2. Over-the-counter Drugs
7. Market By Distribution Channel
7.1. Hospital Pharmacies
7.2. Drug Stores
7.3. Online Pharmacies
7.4. Other Distribution Channel
8. Market By Dosage Form
8.1. Liquid Ophthalmic Drugs Forms
8.2. Solid Ophthalmic Drugs Forms
8.3. Semisolid Ophthalmic Drugs Forms
8.4. Multicompartment Drug Delivery Systems
8.5. Other Ophthalmic Drugs Forms
9. Market By Therapeutic Class
9.1. Anti-glaucoma
9.2. Anti-infective
9.3. Anti-inflammatory
9.4. Anti-allergy
10. Market By Technology
10.1. Biologics
10.2. Cell Therapy
10.3. Gene Therapy
10.4. Drug Delivery
10.5. Small Molecule
10.6. Other Technology
11. Key Analytics
11.1. Porter’s Five Forces Analysis
11.1.1. Bargaining Power Of Buyers
11.1.2. Bargaining Power Of Supplier
11.1.3. Threats Of New Entrants
11.1.4. Threats Of Substitutes
11.1.5. Competitive Rivalry
11.2. Value Chain Analysis
11.2.1. Research And Development
11.2.2. Manufacturing
11.2.3. Marketing And Distribution
11.3. Regulatory Framework
11.4. Opportunity Matrix
12. Geographical Analysis
12.1. Europe
12.1.1. Germany
12.1.2. The United Kingdom
12.1.3. France
12.1.4. Italy
12.1.5. Spain
12.1.6. Rest Of Europe
13. Company Profiles
13.1. Abbott Laboratories
13.2. Allergan Inc.
13.3. Johnson And Johnson
13.4. Bayer
13.5. Valeant
13.6. Regeneron
13.7. Pfizer Inc.
13.8. Merck & Co.
13.9. Novartis Ag
13.10. Glaxosmithkline
13.11. Eyegate Pharmaceuticals
13.12. Apollo Endosurgery
13.13. Roche Holding Ag
13.14. Cipla Pharmaceuticals
13.15. Senju Pharmaceutical Co., Ltd.
13.16. Sun Pharmaceuticals Industries, Ltd.
List Of Tables
Table 1 Europe Ophthalmic Drugs Market Revenue 2019-2027 ($ Million)
Table 2 Common Causes Of Loss Of Vision In The Elderly
Table 3 Eye Drugs Gone Off-patent
Table 4 Europe Ophthalmic Drugs Market By Indication 2019-2027 ($ Million)
Table 5 Europe Dry Eye Market 2019-2027 ($ Million)
Table 6 Europe Ophthalmic Drugs Market By Dry Eye 2019-2027 ($ Million)
Table 7 Europe Glaucoma Market 2019-2027 ($ Million)
Table 8 Europe Infection/Inflammation/Allergy Market 2019-2027 ($ Million)
Table 9 Europe Retinal Disorders Market 2019-2027 ($ Million)
Table 10 Europe Wet Age-related Macular Degeneration Market 2019-2027 ($ Million)
Table 11 Europe Dry Age-related Macular Degeneration Market 2019-2027 ($ Million)
Table 12 Europe Diabetic Retinopathy Market 2019-2027 ($ Million)
Table 13 Europe Other Retinal Disorders Market 2019-2027 ($ Million)
Table 14 Europe Other Indication Market 2019-2027 ($ Million)
Table 15 Europe Ophthalmic Drugs Market By Type 2019-2027 ($ Million)
Table 16 Europe Prescription Drugs Market 2019-2027 ($ Million)
Table 17 Europe Over-the-counter Drugs Market 2019-2027 ($ Million)
Table 18 Europe Ophthalmic Drugs Market By Distribution Channel 2019-2027 ($ Million)
Table 19 Europe Hospital Pharmacies Market 2019-2027 ($ Million)
Table 20 Europe Drug Stores Market 2019-2027 ($ Million)
Table 21 Europe Online Pharmacies Market 2019-2027 ($ Million)
Table 22 Europe Other Distribution Channel Market 2019-2027 ($ Million)
Table 23 Europe Ophthalmic Drugs Market By Dosage Form 2019-2027 ($ Million)
Table 24 Europe Liquid Ophthalmic Drugs Forms Pharmacies Market 2019-2027 ($ Million)
Table 25 Europe Solid Ophthalmic Drugs Forms Market 2019-2027 ($ Million)
Table 26 Europe Semisolid Ophthalmic Drugs Forms Market 2019-2027 ($ Million)
Table 27 Europe Multicompartment Drug Delivery Systems Market 2019-2027 ($ Million)
Table 28 Europe Other Ophthalmic Drugs Forms Market 2019-2027 ($ Million)
Table 29 Europe Ophthalmic Drugs Market By Therapeutic Class 2019-2027 ($ Million)
Table 30 Europe Anti-glaucoma Market 2019-2027 ($ Million)
Table 31 Europe Anti-infective Market 2019-2027 ($ Million)
Table 32 Europe Anti-inflammatory Market 2019-2027 ($ Million)
Table 33 Europe Anti-allergy Market 2019-2027 ($ Million)
Table 34 Europe Ophthalmic Drugs Market By Technology 2019-2027 ($ Million)
Table 35 Europe Biologics Market 2019-2027 ($ Million)
Table 36 Europe Cell Therapy Market 2019-2027 ($ Million)
Table 37 Europe Gene Therapy Market 2019-2027 ($ Million)
Table 38 Europe Drug Delivery Market 2019-2027 ($ Million)
Table 39 Europe Small Molecule Market 2019-2027 ($ Million)
Table 40 Europe Other Technology Market 2019-2027 ($ Million)
Table 41 Europe Ophthalmic Drugs Market By Country 2019-2027 ($ Million)
List Of Figures
Figure 1 Europe Ophthalmic Drugs Market By Glaucoma 2019-2027 ($ Million)
Figure 2 Europe Ophthalmic Drugs Market By Infection /Inflammation /Allergy 2019-2027 ($ Million)
Figure 3 Europe Ophthalmic Drugs Market By Retinal Disorders 2019-2027 ($ Million)
Figure 4 Europe Retinal Disorders Market By Wet Age-related Macular Degeneration 2019-2027 ($ Million)
Figure 5 Europe Retinal Disorders Market By Dry Age-related Macular Degeneration 2019-2027 ($ Million)
Figure 6 Europe Retinal Disorders Market By Diabetic Retinopathy 2019-2027 ($ Million)
Figure 7 Europe Retinal Disorders Market By Other Retinal Disorders 2019-2027 ($ Million)
Figure 8 Europe Ophthalmic Drugs Market By Other Indication 2019-2027 ($ Million)
Figure 9 Europe Ophthalmic Drugs Market By Prescription Drugs 2019-2027 ($ Million)
Figure 10 Europe Ophthalmic Drugs Market By Over-the-counter Drugs 2019-2027 ($ Million)
Figure 11 Europe Ophthalmic Drugs Market By Hospital Pharmacies 2019-2027 ($ Million)
Figure 12 Europe Ophthalmic Drugs Market By Drug Stores 2019-2027 ($ Million)
Figure 13 Europe Ophthalmic Drugs Market By Online Pharmacies 2019-2027 ($ Million)
Figure 14 Europe Ophthalmic Drugs Market By Other Distribution Channel 2019-2027 ($ Million)
Figure 15 Europe Ophthalmic Drugs Market By Liquid Ophthalmic Drugs Forms 2019-2027 ($ Million)
Figure 16 Europe Ophthalmic Drugs Market By Solid Ophthalmic Drugs Forms 2019-2027 ($ Million)
Figure 17 Europe Ophthalmic Drugs Market By Semisolid Ophthalmic Drugs Forms 2019-2027 ($ Million)
Figure 18 Europe Ophthalmic Drugs Market By Multicompartment Drug Delivery Systems 2019-2027 ($ Million)
Figure 19 Europe Ophthalmic Drugs Market By Other Ophthalmic Drugs Forms 2019-2027 ($ Million)
Figure 20 Europe Ophthalmic Drugs Market By Anti-glaucoma 2019-2027 ($ Million)
Figure 21 Europe Ophthalmic Drugs Market By Anti-infective 2019-2027 ($ Million)
Figure 22 Europe Ophthalmic Drugs Market By Anti-inflammatory 2019-2027 ($ Million)
Figure 23 Europe Ophthalmic Drugs Market By Anti-allergy 2019-2027 ($ Million)
Figure 24 Europe Ophthalmic Drugs Market By Biologics 2019-2027 ($ Million)
Figure 25 Europe Ophthalmic Drugs Market By Cell Therapy 2019-2027 ($ Million)
Figure 26 Europe Ophthalmic Drugs Market By Gene Therapy 2019-2027 ($ Million)
Figure 27 Europe Ophthalmic Drugs Market By Drug Delivery 2019-2027 ($ Million)
Figure 28 Europe Ophthalmic Drugs Market By Small Molecule 2019-2027 ($ Million)
Figure 29 Europe Ophthalmic Drugs Market By Other Technology 2019-2027 ($ Million)
Figure 30 Europe Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 31 Development Of The European Population Aged 65 And Over, 2010, 2025 & 2050 (In Million)
Figure 32 Germany Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 33 The United Kingdom Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 34 Projected Number Of People Living With Sight Loss In The Uk (In Million)
Figure 35 Population Aged 65 And Above In France (% Of Total)
Figure 36 France Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 37 Italy Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 38 Spain Ophthalmic Drugs Market 2019-2027 ($ Million)
Figure 39 Rest Of Europe Ophthalmic Drugs Market 2019-2027 ($ Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report